Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004349 · ClinicalTrials.gov registry record
Autoimmune and Autoinflammatory Genetics Study
A clinical trial of Autoimmune Disease and Rheumatic Disease, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 2
- Study locations
NCT06004349 is a study of Autoimmune Disease and Rheumatic Disease that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 1,500 participants, above the 1,361-participant average among 10 other Autoimmune Disease trials with a reported enrollment target (10% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT06004349, a study of Autoimmune Disease and Rheumatic Disease, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.
Conditions Studied
Study Locations (2)
New York
- NYC H+H/Bellevue - New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2032-04-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06004349
The ClinicalTrials.gov registry entry for NCT06004349 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,361-participant average among 10 other Autoimmune Disease trials with a reported enrollment target (10% higher). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Autoimmune Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06004349 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06004349 about?
NCT06004349 is a clinical study titled "Autoimmune and Autoinflammatory Genetics Study". This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collec...
What is the current status of trial NCT06004349?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2022-04-15. Estimated completion is 2032-04-05.
What conditions does trial NCT06004349 study?
This clinical trial studies the following conditions: Autoimmune Disease, Rheumatic Disease, Autoinflammatory Disease, VEXAS Syndome.
Who is sponsoring clinical trial NCT06004349?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004349 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Natural History of Bronchiectasis
RECRUITING
-
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.